TABLE 1 

Proposed predominant metabolic pathway mediating the formation of M1 or M2 in multispecies’ hepatic S9 (2 mg/ml) determined from incubations of VU238 (5 μM) or M1 (VU922, 5 μM) with the AO inhibitor hydralazine (50 μM) or the XO inhibitor allopurinol (100 μM)

Designations of AO or XO indicate that formation of the metabolite was inhibited predominantly by either hydralazine or allopurinol, respectively.

M1M2
HumanaAOn.d.
CynomolgusAOAO
RhesusAOAO
RatAOXO
MouseAOXO
Guinea pigAOAO
MinipigAOn.d.
Female cynomolgusAOn.d.
Female ratAOXO
  • n.d., not determined.

  • a Human data obtained using mixed-gender S9. All other data were obtained using male S9 unless otherwise indicated.